Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsJan 27 08:31 ET

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating

Moomoo NewsJan 27 07:31 ET

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6

Moomoo NewsJan 25 17:32 ET

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Axsome Therapeutics (AXSM) and HCA Healthcare (HCA)

TipRanksJan 25 17:02 ET

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsJan 24 13:32 ET

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6

Moomoo NewsJan 16 06:33 ET

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsJan 15 21:31 ET

JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21

Moomoo NewsJan 15 09:31 ET

Perspective Therapeutics' Strategic Advancements and Positive Clinical Developments Justify Buy Rating

TipRanksJan 15 09:26 ET

RBC Capital Reiterates Outperform on Perspective Therapeutics, Maintains $16 Price Target

BenzingaJan 14 11:45 ET

Perspective Therapeutics Analyst Ratings

BenzingaJan 14 11:44 ET

Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating

Moomoo NewsJan 14 07:36 ET

Perspective Therapeutics (CATX) Receives a Buy From Truist Financial

TipRanksJan 14 07:21 ET

Perspective Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesNov 25, 2024 10:56 ET

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6

Moomoo NewsNov 25, 2024 10:33 ET

B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6

BenzingaNov 25, 2024 08:06 ET

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16

Moomoo NewsNov 25, 2024 07:31 ET

RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk

MT NewswiresNov 25, 2024 07:08 ET

Cautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety Concerns

TipRanksNov 25, 2024 06:08 ET

Perspective Therapeutics Price Target Cut to $16.00/Share From $22.00 by Oppenheimer

Dow JonesNov 22, 2024 09:32 ET